AARD Stock Summary and Trading Ideas (Aardvark Therapeutics | NASDAQ:AARD)

Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.

Aardvark Therapeutics trades on the NASDAQ stock market under the symbol AARD.

As of April 8, 2026, AARD stock price declined to $3.93 with 125,825 million shares trading.

AARD has a beta of 1.94, meaning it tends to be more sensitive to market movements. AARD has a correlation of 0.07 to the broad based SPY ETF.

AARD has a market cap of $85.74 million. This is considered a Micro Cap stock.

The top ETF exchange traded funds that AARD belongs to (by Net Assets): VTI, VXF, IWM, VTWO, IBB.

AARD has underperformed the market in the last year with a return of -50.5%, while the SPY ETF gained +35.5%. In the last 3 month period, AARD fell short of the market, returning -71.3%, while SPY returned -1.7%. However, in the most recent 2 weeks AARD has outperformed the stock market by returning +4.2%, while SPY returned +3.5%.

AARD support price is $3.79 and resistance is $4.29 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AARD shares will trade within this expected range on the day.